hydrochlorothiazide has been researched along with Chronic Kidney Diseases in 22 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per day)." | 5.34 | A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. ( Bovée, DM; Danser, AHJ; De Mik-van Egmond, A; Greupink, R; Hoorn, EJ; Masereeuw, R; Middel, I; Russel, FGM; Visser, WJ; Zietse, R, 2020) |
| "BEAHIT (Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients with Hypertension) was approved by Changzheng Hospital Ethics Committee (CZ-20160504-16)." | 5.24 | Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. ( Dai, B; Lv, J; Mei, C; Wang, Y; Xue, C; Yang, B; Yu, S; Zhao, G; Zhou, C, 2017) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| " Alcohol consumption, female sex, n-terminal pro-brain natriuretic peptide (NT-proBNP), hydrochlorothiazide (HCT), and mineralocorticoid receptor antagonist (MRA) use, or angiotensin II receptor I blocker (ARB) non-use were associated with hyponatremia in patients with normal renal function (p ≤ 0." | 4.12 | Clinical predictors of hyponatremia in patients with heart failure according to severity of chronic kidney disease. ( Bušić, Ž; Čulić, V; Velat, I, 2022) |
| "This cohort study found that among older adults, chlorthalidone use was associated with a higher risk of eGFR decline, cardiovascular events, and hypokalemia compared with hydrochlorothiazide use." | 4.02 | Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. ( Bugeja, A; Burns, K; Canney, M; Edwards, C; Hundemer, GL; Knoll, G; Petrcich, W; Sood, MM, 2021) |
| " AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ." | 2.87 | Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. ( Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, C | 1 |
| Hundemer, GL | 1 |
| Petrcich, W | 1 |
| Canney, M | 1 |
| Knoll, G | 1 |
| Burns, K | 1 |
| Bugeja, A | 1 |
| Sood, MM | 1 |
| Velat, I | 1 |
| Bušić, Ž | 1 |
| Čulić, V | 1 |
| Bovée, DM | 1 |
| Visser, WJ | 1 |
| Middel, I | 1 |
| De Mik-van Egmond, A | 1 |
| Greupink, R | 1 |
| Masereeuw, R | 1 |
| Russel, FGM | 1 |
| Danser, AHJ | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Bossoni, S | 1 |
| Chiesa, L | 1 |
| Giustina, A | 1 |
| van der Merwe, WM | 1 |
| Bakris, GL | 1 |
| Zhao, L | 1 |
| Kupfer, S | 1 |
| Juhasz, A | 1 |
| Hisada, M | 1 |
| Lloyd, E | 1 |
| Oparil, S | 1 |
| Arias, SC | 1 |
| Valente, CP | 1 |
| Machado, FG | 1 |
| Fanelli, C | 1 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Malheiros, DM | 1 |
| Zatz, R | 2 |
| Fujihara, CK | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Nasr, SH | 1 |
| Milliner, DS | 1 |
| Wooldridge, TD | 1 |
| Sethi, S | 1 |
| Chrysant, SG | 2 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 1 |
| Ando, K | 1 |
| Nitta, K | 1 |
| Rakugi, H | 1 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 1 |
| Tomita, K | 1 |
| Nangaku, M | 2 |
| Takahashi, K | 1 |
| Isshiki, M | 1 |
| Shimosawa, T | 1 |
| Fujita, T | 1 |
| Hayashi, M | 1 |
| Uchida, S | 1 |
| Kawamura, T | 1 |
| Kuwahara, M | 1 |
| Iino, Y | 1 |
| Vasco, RF | 1 |
| Moyses, RM | 1 |
| Elias, RM | 1 |
| Xue, C | 1 |
| Zhou, C | 1 |
| Yang, B | 1 |
| Lv, J | 1 |
| Dai, B | 1 |
| Yu, S | 1 |
| Wang, Y | 1 |
| Zhao, G | 1 |
| Mei, C | 1 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Matsumoto, S | 1 |
| Matsumoto, K | 1 |
| Greathouse, MK | 1 |
| Weir, MR | 2 |
| Karadsheh, F | 1 |
| Kereiakes, DJ | 1 |
| Izzo, JL | 1 |
| Littlejohn, T | 1 |
| Melino, M | 1 |
| Lee, J | 1 |
| Fernandez, V | 1 |
| Heyrman, R | 1 |
| Suzuki, H | 1 |
| Shimada, Y | 1 |
| Fujiwara, K | 1 |
| SACKNER, MA | 1 |
| WALLACK, AA | 1 |
| BELLET, S | 1 |
| SHULGA, IuD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886] | Phase 4 | 28 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828] | Phase 3 | 153 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial[NCT02646397] | Phase 4 | 508 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 69.3 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 78.4 |
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 58.7 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 73.0 |
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 80.0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 87.8 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Adverse Events | Adverse Events Leading to Discontinuation | Serious Adverse Events | Serious Adverse Events Leading to Discontinuation | Death | |
| Azilsartan Medoxomil + Chlorthalidone | 68 | 17 | 8 | 5 | 0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 58 | 15 | 9 | 4 | 1 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
3 reviews available for hydrochlorothiazide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Co | 2012 |
Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease.
Topics: Antihypertensive Agents; Chlorthalidone; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hy | 2012 |
9 trials available for hydrochlorothiazide and Chronic Kidney Diseases
| Article | Year |
|---|---|
A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease.
Topics: Adult; Aged; Amiloride; Blood Pressure Determination; Cross-Over Studies; Diet, Sodium-Restricted; D | 2020 |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Topics: Aged; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2018 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2015 |
Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2017 |
Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2010 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-B | 2012 |
10 other studies available for hydrochlorothiazide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function.
Topics: Aged; Chlorthalidone; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration | 2021 |
Clinical predictors of hyponatremia in patients with heart failure according to severity of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Calcium Chan | 2022 |
Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Calcium; Calcium Gluconate; Coronav | 2020 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Triamterene crystalline nephropathy.
Topics: Antihypertensive Agents; Biopsy; Creatinine; Diagnostic Errors; Drug Combinations; Drug-Related Side | 2014 |
Furosemide Increases the Risk of Hyperparathyroidism in Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Calcium; Diuretics; Female; Furosemide; Humans; Hydrochlorothiazide; Hyperp | 2016 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
The diuretic effects of hydrochlorothiazide in congestive heart failure, cirrhosis, chronic renal disease and hypertension: preliminary report based on a study of 28 cases.
Topics: Acetazolamide; Diuretics; Edema; Heart Failure; Hydrochlorothiazide; Hypertension; Kidney Failure, C | 1959 |
[APPLICATION OF HYPOTHIAZIDE IN CHRONIC KIDNEY DISEASES].
Topics: Acute Kidney Injury; Blood Chemical Analysis; Glomerulonephritis; Hydrochlorothiazide; Hypertension; | 1963 |